Electronic Supplementary Information (ESI)

Tuning the Potential in Redox-active Diphosphine Ligands Based on the Alkyne Complexes $[Tp^*W(CO)L{\eta^2-C_2(PPh_2)}_2]$

Stephan Ludwig,^a Friederike M. Hamann,^{a,b} Kai Helmdach,^a Alexander Villinger^a, and Wolfram W. Seidel,^{*a,b}

^aInstitut für Chemie, Universität Rostock, Albert-Einstein-Straße 3a, 18059 Rostock, Germany. Email: wolfram.seidel@uni-rostock.de ^bLeibniz Institut für Katalyse e.V., Albert-Einstein-Straße 29a, 18059 Rostock, Germany

Content

1	Syntheses and analytical data	2
2	¹³ C NMR shift / CO vibration correlations	12
3	X-ray analysis	13
4	NMR spectra of selected compounds	22
5	References	36

1 Syntheses and Analytical Data

1.1 General

All operations were carried out in an atmosphere of dry argon using Schlenk and glove box techniques. Solvents for reactions were dried and saturated with argon by standard methods and freshly distilled prior to use. Solvents for chromatography were used as purchased from commercial sources. NMR spectra were recorded at 300 K using Bruker Avance 250, 300 or 500 MHz spectrometers. In ¹H and ¹³C NMR, the chemical shifts were internally referenced to the solvent residual peak and in ³¹P NMR, H₃PO₄ was used as external standard. IR spectroscopy was conducted on a Bruker ALPHA-T for solid-state measurements as well as those in solution. Elemental analyses were performed with a Thermo Finnigan Flash EA 1112 Series. CV experiments were performed using a Princeton Applied Research VersaSTAT 3 potentiostat. A three-electrode arrangement with a glassy carbon working electrode, a platinum wire counter electrode and a Ag/AgBF₄ in CH₃CN reference electrode was employed. A 0.1 M n-Bu₄N⁺PF₆⁻ solution was used as supporting electrolyte. The Fc/Fc⁺ redox couple was used as internal standard. The starting materials [Tp*W(CO)₃], 1,^{S1} and $Fc^+PF_6^{-S2}$ were synthesized according to literature procedures. We have described the syntheses of iodide complexes 3^I, 4^I and 5^I as well as cyanide complexes 3^{CN}, 4^{CN} and 5^{CN} elsewhere.^{S1} All other reagents were used as purchased from commercial sources.

1.2 [Tp*W(CO)L(η^2 -C₂H₂)] 3^L

1.2.1 3^{SCPy}



In a 100 mL Schlenk flask, 1488 mg (2.05 mmol) 3^{oTf} and 392 mg (2.66 mmol) sodium 2-pyridylmethanethiolate were dissolved in 50 mL of THF. After 90 min, the color had changed from blue to purple and the progress of the reaction was checked by IR spectroscopy. The solvent was removed under reduced pressure and the crude product was purified by column chromatography using pure Et₂O as eluent.

After drying in vacuo, the solid product was obtained as a light purple foam. Yield: 1269 mg (88 %).

¹**H NMR** (CDCl₃, 300 MHz, 298 K): δ (ppm) = 12.02 (s, br, 1 H, alkyne-*H*), 10.93 (s, 1 H, alkyne-*H*), 8.47 (bd, 1 H, Py-*H*), 7.48 (s, br, 1 H, Py-*H*), 7.02 (m, br, 1 H, Py-*H*), 2.70 (s, 3 H, CH₃), 2.54 (s, 3 H, CH₃), 2.47 (s, 3 H, CH₃), 2.28 (s, 3 H, CH₃), 2.25 (s, 3 H, CH₃), 2.00 (s, 3 H, CH₃), 1.84 (s, 3 H, CH₃), 1.75 (s, 3 H, CH₃), 1.70 (s, 3 H, CH₃). ¹³**C NMR** (CDCl₃, 75 MHz, 298 K): δ (ppm) = 228.9 (CO), 185.8 (b, WCH), 176.1 (b, WCH), 151.7, 147.5, 142.0, 140.1, 123.0 (^{3.5}CCH₃), 163.2 (Py-C-Me), 152.4 (b, Py-C-H), 148.7, 135.8, 120.6 (Py-C-H), 113.7, 112.6, 112.1 (⁴CCH₃), 85.9 (CH₂), 15.2 (CCH₃), 14.8 (CCH₃), 14.3 (CCH₃), 13.6

(CCH₃), 11.0 (CCH₃), 10.9 (CCH₃), 8.4 (CCH₃), 8.2 (CCH₃). **IR** (ATR, cm⁻¹): 2543 (w, BH), 1875 (s, CO). **IR** (THF, cm⁻¹): 2549 (w, BH), 1889 (s, CO). **Anal.** Calc. for $C_{27}H_{36}BN_7OSW$ (701.34 g/mol)·0.5 $C_4H_{10}O$: C, 47.17; H, 5.60; N, 13.28; S, 4.34. Found: C, 47.79; H, 5.57; N, 13.39; S, 4.18.

1.2.2 3^{SPh}



In a 100 mL Schlenk flask, 1165 mg (1.60 mmol) **3**^{oTf} and 276 mg (2.09 mmol) sodium thiophenolate were suspended in 40 mL of THF. After 30 min of stirring in a warm water bath, the colour changed from light blue to deep blue, while the progress of the reaction was checked by IR spectroscopy. The solvent was removed under reduced pressure

and the crude product was purified by column chromatography using CH_2Cl_2 /petroleum ether 1:1 as eluent. The blue fraction was collected and dried *in vacuo*. Yield 738 mg (67 %).

¹**H NMR** (CDCl₃, 500 MHz, 298 K): δ (ppm) = 12.66 (s, 1 H, alkyne-*H*), 11.30 (d, 1 H, alkyne-*H*), 7.32-7.07 (m, 5 H, Ph-*H*), 2.53 (s, 3 H, C*H*₃), 2.50 (s, br, 3 H, C*H*₃), 2.32 (s, 3 H, C*H*₃), 2.30 (s, 3 H, C*H*₃), 2.27 (s, br, 3 H, C*H*₃), 2.01 (s, 3 H, C*H*₃), 1.82 (s, 3 H, C*H*₃), 1.80 (s, 3 H, C*H*₃), 1.74 (s, 3 H, C*H*₃). ¹³**C NMR** (CDCl₃, 63 MHz, 299 K): δ (ppm) = 232.7 (CO), 188.9 (WCH), 179.3 (WCH), 152.6, 152.2, 150.0, 147.4, 142.1, 141.0 (^{3.5}CCH₃), 131.7, 127.5, 124.6 (Ph-C), 113.8, 112.7, 111.2 (⁴CCH₃), 14.6, 14.3, 13.6, 11.0, 11.0, 11.0, 8.4, 8.2, 8.0 (CCH₃). **IR** (ATR, cm⁻¹): 2543 (w, BH), 1890 (s, CO). **IR** (THF, cm⁻¹): 2548 (w, BH), 1902 (s, CO). **Anal.** Calc. for C₂₇H₃₅BN₆OSW (686.32 g/mol)·0.5 C₅H₁₂: C, 49.05; H, 5.72; N, 11.63; S, 4.44. Found: C, 49.52; H, 5.88; N, 11.25; S, 3.97.

1.2.3 3^F



A solution of 2.00 g (3.30 mmol) **1** in 60 mL CH_2CI_2 was saturated with acetylene by a vigorous gas stream for ten minutes. Then, with further purging with acetylene, a total of 1.09 g (3.30 mmol) of ferrocenium hexafluorophosphate was added in eight portions every four minutes. A few minutes after the addition of the last portion, the progress of the

reaction was checked by IR spectroscopy. The intermediate was dried *in vacuo* and most of the ferrocene formed was removed by washing eight times with 10 mL of Et_2O . The green solid was dissolved in 40 mL of THF, and the solution was cooled to -60 °C. A solution of 1.35 g (4.29 mmol) *n*-NBu₄F in 10 mL THF was then added. After about twenty minutes, the progress of the reaction was checked again by IR. At full conversion, the solution was warmed to room temperature using a water bath and the solvent was removed *in vacuo*. The

crude product was purified by column chromatography using an eluent mixture of CH_2Cl_2 , Et_2O and petroleum ether in the ratio 5:1:1. Removal of the solvent in vacuum resulted in a light blue powder. Yield: 1.27 g (65 %).

¹H NMR (CDCl₃, 300 MHz, 298 K): δ (ppm) = 13.29 (s, 1 H, alkyne-*H*), 11.80 (s, 1 H, alkyne-*H*), 2.65 (s, 3 H, *CH*₃), 2.41 (s, 3 H, *CH*₃), 2.37 (s, 3 H, *CH*₃), 2.29 (s, 3 H, *CH*₃), 2.24 (s, 3 H, *CH*₃), 1.97 (s, 3 H, *CH*₃), 1.89 (s, 3 H, *CH*₃), 1.75 (s, 3 H, *CH*₃), 1.72 (s, 3 H, *CH*₃). ¹³C NMR (CDCl₃, 63 MHz, 298 K): δ (ppm) =238.2 (CO), 195.7 (WCH), 191.3 (WCH), 150.3, 150.3, 147.5, 143.4, 141.2, 140.4 (^{3.5}CCH₃), 113.0, 112.7, 112.6 (⁴CCH₃), 14.1, 12.8 (d, *J*_{CF} = 4.5 Hz), 12.1 (d, *J*_{CF} = 6.4 Hz), 11.0, 10.6, 10.5, 8.3, 8.0, 7.8 (CCH₃). ¹⁹F NMR (CDCl₃, 282 MHz, 298 K): δ (ppm) = -95.8 (W*F*). IR (ATR, cm⁻¹): 2532 (w, BH), 1875 (s, CO). IR (THF, cm⁻¹): 2543 (w, BH), 1887 (s, CO). Anal. Calc. for C₂₁H₃₀BFN₆OW (596.15 g/mol): C, 42.31; H, 5.07; N, 14.10. Found: C, 42.35; H, 5.25; N, 14.00.

1.2.4 3^{CI}



In a 500 mL Schlenk flask, 12.00 g (19.76 mmol) **1** were dissolved in 200 mL CH₂Cl₂. Acetylene was introduced into the flask from an acetylene gas cylinder, ensuring pressure equalization via syringe and septum. 6.54 g (19.76 mmol) of $FcPF_6$ were added in 5 portions every 5 minutes. The solvent was removed from the green solution *in vacuo*. 100 mL of Et₂O

was added and after one hour of vigorous stirring the orange solution was decanted. After dissolving in 120 mL of THF, 11 g (39.58 mmol) of *n*-NBu₄Cl was added. After checking the reaction progress by IR and removing the solvent *in vacuo*, the mixture was treated with 100 mL methanol and 3^{cl} was filtered off over a G3 frit. The light blue product was washed with 20 mL methanol and 10 mL Et₂O and dried overnight. Yield: 7.07 g (58 %).

¹H NMR (CDCl₃, 300 MHz, 298 K): δ (ppm) =13.41 (s, 1H, alkyne-*H*), 12.12 (s, 1H, alkyne-*H*), 2.72 (s, 3H, C*H*₃), 2.48 (s, 3H, C*H*₃), 2.46 (s, 3H, C*H*₃), 2.37 (s, 3H, C*H*₃), 2.28 (s, 3H, C*H*₃), 2.00 (s, 3H, C*H*₃), 1.86 (s, 3H, C*H*₃), 1.75 (s, 3H, C*H*₃), 1.72 (s, 3H, CH₃). ¹³C NMR (CDCl₃, 75 MHz, 298 K): δ (ppm) = 232.9 (CO), 202.9 (WCH), 195.2 (WCH), 152.3, 151.8, 147.5, 143.3, 141.5, 140.6 (^{3.5}CCH₃), 113.6, 113.0, 112.7 (⁴CCH₃), 14.4, 14.1, 13.7, 11.0, 10.9, 10.8, 8.3, 8.3, 8.0 (CCH₃). **IR** (ATR, cm⁻¹): 2541 (w, BH), 1883 (s, CO). **IR** (THF, cm⁻¹): 2551 (w, BH), 1907 (s, CO). **Anal.** Calc. for C₂₁H₃₁BCIN₆OW (613.61 g/mol): C, 41.10; H, 5.09; N, 13.70. Found: C, 42.03; H, 5.04; N, 12.42.

1.3 [Tp*W(CO)L(η^2 -C₂{H}{PPh₃}] 4^L

1.3.1 4^{SCPy}



In a 100 mL Schlenk flask, 663 mg (903 µmol) 3^{SCPy} dissolved in
PPh₂ 40 mL THF were cooled to -80 °C and 0.47 mL (1.18 mmol) of 2.5 M n-BuLi solution in hexane was added. After 15 min, 0.27 mL (1.46 mmol) Ph₂PCI was added. After warming to room temperature, the solvent was removed under reduced pressure

and the residue was transferred on top of a chromatography column packed with CH_2Cl_2 . After all by-products elutable with CH_2Cl_2 passed the column, the blue product was collected with a mixture of CH_2Cl_2 and MeCN in a 10:1 ratio and dried *in vacuo*. Yield: 526 mg (66 %).

¹**H NMR** (CDCl₃, 300 MHz, 298 K): *δ* (ppm) = 11.89 (s, br, 1 H, alkyne-*H*), 8.55 (d, 1 H, Py-*H*), 7.61 (m, 1 H, Py-*H*), 7.47-7.09 (m, 8 H, Ph-*H*, Py-*H*), 6.88 (m, 2 H, Ph-*H*), 8.38 (m, 2 H, Ph-*H*), 5.50 (s, br, 1 H, C*H*₂), 4.99 (s, br, 1 H, C*H*₂), 2.70 (s, 3 H, C*H*₃), 2.46 (s, 6 H, C*H*₃), 2.21 (d, 3 H, C*H*₃), 2.20 (s, 6 H, C*H*₃), 1.82 (s, 3 H, C*H*₃), 1.74 (s, 3 H, C*H*₃), 1.52 (s, 3 H, C*H*₃), 1.3 (s, 3 H, C*H*₃). ¹³**C NMR** (CDCl₃, 63 MHz, 300 K): *δ* (ppm) = 191.2 (d, ¹*J*_{CP} = 52.2 Hz, WCP)), 189.4 (br, WCH), 163.1 (Py-C), 152.2, 151.6, 148.4, 147.2, 141.6, 141.1, 140.7, 140.4 (^{3.5}CCH₃, Py-C), 135.8, 134.6, 134.3, 131.4, 131.1, 128.1-127.8, 127.4, 127.2, 127.1 (Ph-C), 123.2, 120.5 (Py-C), 113.0, 112.5, 112.4 (⁴CH), 51.3 (b, CH₂), 16.6, 16.3, 14.6, 13.0, 11.0, 10.8, 8.3, 8.1 (CCH₃). ³¹**P NMR** (CDCl₃, 121 MHz, 298 K): *δ* (ppm) = 12.4 (WC*P*). **IR** (ATR, cm⁻¹): 2545 (w, BH), 1879 (s, CO). **IR** (THF, cm⁻¹): 2550 (w, BH), 1892 (s, CO). **Anal.** Calc. for C₃₉H₄₅BN₇OPSW (885.51 g/mol): C, 52.90; H, 5.12; N, 11.07; S, 3.62. Found: C, 53.00; H, 4.95; N, 10.42; S, 3.31.

1.3.2 4^{SPh}



In a 100 mL Schlenk flask, 720 mg (1.05 mmol) 3^{SPh} dissolved in 50 mL THF were cooled to -80 °C and 0.55 mL (1.38 mmol) of 2.5 M *n*-BuLi solution in hexane were added. After 10 min, 0.31 mL (1.68 mmol) Ph₂PCI were added. After coming to room temperature, the solvent was removed *in vacuo* and the residue was purified by

column chromatography with pure Et_2O . A second chromatography step using an eluent mixture of CH_2Cl_2 /petroleum ether 1/1 followed. The product **4**^{SPh} was obtained as a blue solid after removal of the solvents *in vacuo*. Yield: 410 mg (45 %).

¹**H NMR** (CDCl₃, 300 MHz, 298 K): δ (ppm) = 12.73 (s, 1 H, alkyne-*H*), 7.40-7.07 (m, 11 H, Ph-*H*), 6.88 (m, 2 H, Ph-*H*), 6.40 (m, 2 H, Ph-*H*), 2.46 (s, 3 H, C*H*₃), 2.40 (d, 3 H, C*H*₃,

 $J_{\text{HP}} = 1.13 \text{ Hz}$), 2.22 (s, 3 H, CH_3), 2.18 (s, 3 H, CH_3), 2.17 (s, 3 H, CH_3), 1.74 (s, 3 H, CH_3), 1.72 (s, 3 H, CH_3), 1.51 (s, 3 H, CH_3), 1.36 (s, 3 H, CH_3). ¹³**C NMR** (CDCl₃, 75 MHz, 298 K): δ (ppm) = 233.9 (CO), 194.3 (d, WCP, ¹ $J_{\text{CP}} = 53.6 \text{ Hz}$), 191.8 (d, WCH, ² $J_{\text{CP}} = 3.7 \text{ Hz}$), 152.2, 150.1, 147.3, 141.7, 140.9, 140.7, (^{3.5}CCH₃), 134.9, 134.5, 131.9, 131.6, 131.4, 128.2-127.2, 124.7 (Ph-C), 113.3, 112.7, 112.6 (⁴CCH₃), 14.7 (CCH₃), 13.0 (CCH₃), 11.4, (CCH₃), 11.1 (CCH₃), 11.0 (CCH₃), 10.8 (CCH₃), 8.3 (CCH₃), 8.2 (CCH₃), 8.1 (CCH₃). ³¹**P NMR** (CDCl₃, 121 MHz, 298 K): δ (ppm) = 12.9 (s, WC*P*). **IR** (ATR, cm⁻¹): 2549 (w, BH), 1892 (s, CO). **IR** (THF, cm⁻¹): 2550 (w, BH), 1907 (s, CO). **Anal.** Calc. for C₃₉H₄₄BN₆OPSW (870.50 g/mol)·0.33 CH₂Cl₂: C, 52.56; H, 5.01; N, 9.35; S, 3.57. Found: C, 52.54, H, 4.97, N, 9.18, S, 3.21.

1.3.3 4^F



In a 100 mL Schlenk flask, 332 mg (557 μ mol) **3**^F dissolved in 40 mL THF were cooled to -80 °C and 0.30 mL (740 μ mol) of 2.5 M n-BuLi solution in hexane were added. After 15 min, 0.15 mL (840 μ mol) Ph₂PCI were added. After coming to room temperature, the solvent was removed under reduced pressure. The residue was recrystallized

several times from CH_2Cl_2/n -pentane, first separating lithium chloride and sus, brequently the product **4**^F. A chromatographic purification is not applicable due to complex decomposition. This sequence yielded solely a small sample of crystalline material.

¹H NMR (CDCl₃, 300 MHz, 298 K): δ (ppm) = 13.27 (s, 1 H, alkyne-*H*), 7.31-7.09 (m, 6 H, Ph-*H*), 6.84 (m, 2 H, Ph-*H*), 6.38 (m, 2 H, Ph-*H*), 2.59 (s, 3 H, C*H*₃), 2.46 (s, 3 H, C*H*₃), 2.19 (s, 3 H, C*H*₃), 2.11 (s, 6 H, C*H*₃), 1.82 (s, 3 H, C*H*₃), 1.76 (s, 3 H, C*H*₃), 1.52 (s, 3 H, C*H*₃), 1.36 (s, 3 H, C*H*₃). ¹³C NMR (CDCl₃, 75 MHz, 298 K): δ (ppm) = 239.2 (s, CO), 201.1 (d, ¹J_{CP} = 52.7 Hz, WCP), 200.0 ((d, ²J_{CP} = 5.5 Hz, WCH), 150.1, 150.0, 147.2, 143.0, 141.1, 139.8 (^{3.5}CCH₃), 135.4-127.1 (m, Ph-C), 112.7, 112.6, 112.4 (⁴CCH₃), 13.6, 13.0, 12.9, 11.2, 10.7, 10.3, 8.4, 7.8, 7.8 (CCH₃). ¹⁹F NMR (CDCl₃, 282 MHz, 298 K): δ (ppm) = -93.6 (s, W*F*). ³¹P NMR (CDCl₃, 121 MHz, 298 K): δ (ppm) = 12.5 (WC*P*). IR (THF, cm⁻¹): 2545 (w, BH), 1893 (s, CO).

1.3.4 4^{CI}



In a 250 mL Schlenk flask, 2.00 g (3.26 mmol) 3^{cl} dissolved in 120 mL THF were cooled to -80 °C and 1.70 mL (4.24 mmol) of 2.5 M n-BuLi solution in hexane were added. After 15 min, 0.96 mL (5.22 mmol) Ph₂PCI were added. After coming to room temperature, the solvent is

removed *in vacuo*. The residue was suspended in 50 mL MeOH and **4**^{CI} was filtered off through a G3 frit. The blue product was washed with 10 mL MeOH and dried overnight in air. Yield 1.59 g (61 %).

¹**H NMR** (CDCl₃, 300 MHz, 300 K): δ (ppm) = 13.34 (s, 1H, alkyne-*H*), 7.28-7.12 (m, 6H, Ph-*H*), 6.87 (m, 2H, Ph-*H*), 6.38 (m, 2H, Ph-*H*), 2.68 (s, 3H, *CH*₃), 2.51 (s, 3H, *CH*₃), 2.28 (d, 3H, *CH*₃, *J*_{HP} = 1.32 Hz), 2.20 (s, 3H, *CH*₃), 2.18 (s, 3H, *CH*₃), 1.80 (s, 3H, *CH*₃), 1.75 (s, 3H, *CH*₃), 1.50 (s, 3H, *CH*₃), 1.25 (s, 3H, *CH*₃). ¹³**C NMR** (CDCl₃, 75 MHz, 300 K): δ (ppm) = 234.0 (CO), 208.3 (WCH), 204.7 (d, WCP, ¹*J*_{CP} = 4.5 Hz), 152.0, 151.8, 147.2, 142.9, 141.4, 140.1 (^{3,5}CCH₃), 134.9, 134.6, 133.5, 131.4, 131.2, 128.4, 128.3, 128.3, 128.1, 127.4, 127.3 (Ph-*C*), 113.0, 113.0, 112.9 (⁴CCH₃), 15.3, 15.1, 14.1, 13.6, 11.1, 11.0, 10.6, 8.5, 8.1 (CCH₃). ³¹**P NMR** (CDCl₃, 121 MHz, 301 K): δ (ppm) = 16.4 (s, WC*P*). **IR** (ATR, cm⁻¹): 2545 (w, BH), 1896 (s, CO). **IR** (THF, cm⁻¹): 2550 (w, BH), 1911 (s, CO). **Anal.** Calc. for C₃₃H₃₉BCIN₆OPW (796.78 g/mol): C, 49.74; H, 4.93; N, 10.55. Found: C, 49.56; H, 5.21; N, 9.80.

1.4 [Tp*W(CO)L(η^2 -C₂{PPh₃}₂)] 5^L

1.4.1 5^{SCPy}



In a 100 mL Schlenk flask, 526 mg (594 μ mol) **4**^{SCPy} dissolved in 30 mL THF were cooled to -80 °C and 0.31 mL (775 μ mol) of a 2.5 M n-BuLi solution in hexane were added. After ten minutes, 0.18 mL (976 μ mol) Ph₂PCI were added. After warming to ambient temperature and removing the solvent *in vacuo*, the crude product was purified by column chromatography using an eluent mixture of

 $CH_2CI_2/MeCN$ 10/1. The product was obtained as a blue-green solid after drying *in vacuo*. Yield 363 mg (57 %).

¹H NMR (CDCl₃, 300 MHz, 298 K): δ (ppm) = 8.45 (bd, 1 H, Py-*H*), 7.72 (s, br, 2 H, Py-*H*), 7.44 (s, br, 1H, Py-*H*), 7.36-7.14 (m, 8 H, Ph-*H*), 7.02 (m, 6 H, Ph-*H*), 6.82 (m, 2 H, Ph-*H*), 6.66 (m, 2 H, Ph-*H*), 6.49 (m, 2 H, Ph-*H*), 2.56 (d, 3 H, C*H*₃, J_{HP} = 2.08 Hz), 2.52 (s, 3 H, C*H*₃), 2.45 (s, 3 H, C*H*₃), 2.25 (s, 3 H, C*H*₃), 2.18 (s, 3 H, C*H*₃), 2.12 (s, 3 H, C*H*₃), 1.97 (s, 3 H, C*H*₃), 1.72 (s, 3 H, C*H*₃), 1.51 (s, 3 H, C*H*₃). ¹³C NMR (CDCl₃, 63 MHz, 300 K): δ (ppm) = 205.0 (m, WCP), 204.2 (m, WCP), 163.9, 151.6, 151.4, 148.6, 142.4, 140.2, 138.9, 137.3 (Py-C, ^{3.5}CCH₃), 133.3-126.9 (Ph-C), 122.7, 120.5 (Py-C), 113.1, 113.1, 112.3 (⁴CH), 16.9 (d, J_{CP} = 19.5 Hz), 15.1 (d, J_{CP} = 12.2 Hz) 14.9, 11.3, 11.0, 10.8, 8.5, 8.3, 8.2 (CCH₃). ³¹P NMR (CDCl₃, 121 MHz, 298 K): δ (ppm) = 13.4 (d, WCP, ³J_{PP} = 10.4 Hz), 11.5 (s, br, WCP). **IR** (ATR, cm⁻¹): 2531 (w, BH), 1914 (s, CO). **IR** (CDCl₃, cm⁻¹): 2553 (w, BH), 1919 (s, CO). **Anal.** Calc. for C₅₁H₅₄BN₇OP₂SW (1069.69 g/mol): C, 57.26; H, 5.09; N, 9.17; S, 3.00. Found: C, 57.30; H, 4.96; N, 8.90; S, 2.79.

1.4.2 5^{SPh}



In a 50 mL Schlenk flask, 280 mg (322 μ mol) of **4**^{SPh} dissolved in 15 mL of THF were cooled to -80 °C and 0.17 mL (425 μ mol) of a 2.5 M n-BuLi solution in hexane were added. After ten minutes, 0.10 mL (542 μ mol) Ph₂PCI were added. After warming to room temperature, the crude product was transferred on top of a

chromatography column packed with Et_2O and all non-polar by-products were eluted first with n-pentane before the product is eluted as a green band with pure Et_2O . After drying *in vacuo*, the product is obtained as a green solid. Yield: 308 mg (91 %).

¹**H NMR** (CDCl₃, 300 MHz, 298 K): δ (ppm) = 7.76 (m, 2 H, Ph-*H*), 7.44 (m, 4 H, Ph-*H*), 7.26 (m, 5 H, Ph-*H*), 7.04 (m, 5 H, Ph-*H*), 6.88 (m, 4 H, Ph-*H*), 6.80 (m, 2 H, Ph-*H*), 6.70 (m, 2 H, Ph-*H*), 6.48 (m, 2 H, Ph-*H*), 2.54 (s, 3 H, C*H*₃), 2.35 (s, 3 H, C*H*₃), 2.22 (s, 3 H, C*H*₃), 2.20 (s, br, 3 H, C*H*₃), 2.14 (s, 3 H, C*H*₃), 2.10 (s, br, 3 H, C*H*₃), 1.98 (s, 3 H, C*H*₃), 1.70 (s, 3 H, C*H*₃), 1.35 (s, 3 H, C*H*₃). ¹³**C NMR** (CDCl₃, 75 MHz, 299 K): δ (ppm) = 233.8 (CO), 151.1, 151.9, 150.1, 142.6, 140.4, 140.2 (^{3.5}CCH₃), 138.4, 138.3, 137.1 (d), 136.5, 136.2, 134.9, 134.6, 134.3, 133.4, 133.1, 131.5, 129.2, 128.9, 128.6, 128.3, 128.2, 128.0, 127.9, 127.6, 127.5, 127.2, 127.0, 126.9 (Ph-C), 113.2, 113.0, 112.5 (⁴CH), 16.7 (d, *J*_{CP} = 18.5 Hz), 15.5 (d, *J*_{CP} = 12.1 Hz), 14.7, 11.4, 11.1, 10.8, 8.6, 8.2, 8.2 (CCH₃). ³¹**P NMR** (CDCl₃, 121 MHz, 299 K): δ (ppm) = 14.3 (d, WCP, ³*J*_{PP} = 10.4 Hz), 13.6 (bd, WCP). **IR** (THF, cm⁻¹): 2550 (w, BH), 1926 (s, CO).

1.4.3 5^F



In a 50 mL Schlenk flask, 175 mg (163 μ mol) **5**^I were dissolved in 20 mL THF and cooled to -80 °C. Sus, brequently, 0.40 mL (200 μ mol) of a 0.5 M *n*-NBu₄F solution in THF was added and the reaction solution was stirred for one hour. After removing the cooling bath, the mixture was heated to 80 °C for two hours under reflux. The solvent

was then removed *in vacuo* and the crude product was subjected to column chromatographic work-up using an eluent mixture of CH_2CI_2 , Et_2O and petroleum ether in the ratio 5/1/1. Care must be taken to use both degassed solvents and deoxygenated silica and to carry out the procedure under inert gas. In the next step, the product obtained is further purified by crystallisation from CH_2CI_2/n -pentane. The product and a by-product that cannot be

separated in bulk were obtained in a ratio of 2/1 in a combined amount of 64 mg. A purer sample for analysis was obtained by picking crystals.

¹**H NMR** (CDCl₃, 300 MHz, 297 K): δ (ppm) = 7.78 (m, 2 H, Ph-*H*), 7.40 (m, 4 H, Ph-*H*), 7.15 (m, 6 H, Ph-*H*), 6.97 (m, 2 H, Ph-*H*), 6.76 (m, 2 H, Ph-*H*), 6.63 (m, 2 H, Ph-*H*), 6.47 (m, 2 H, Ph-*H*), 2.48 (s, 3 H, CH₃), 2.40 (s, 3 H, CH₃), 2.33 (s, 3 H, J_{HP} = 1.32 Hz, CH₃), 2.25 (s, 3 H, CH₃), 2.16 (s, 3 H, CH₃), 2.05 (s, 3 H, CH₃), 1.93 (s, 3 H, CH₃), 1.76 (s, 3 H, CH₃), 1.54 (s, 3 H, CH₃). ¹³**C NMR** (CDCl₃, 75 MHz, 298K): δ (ppm) = 150.0, 149.4, 148.9, 142.9, 140.6, 140.1 (^{3.5}CCH₃), 137.8-126.8 (Ph-*C*), 113.2, 112.7, 112.4 (⁴CH), 15.0 (d, J_{CP} = 10.4 Hz), 14.1 (d, J_{CP} = 16.7 Hz), 13.7, 11.4, 10.8, 10.5, 8.6, 8.1, 8.0 (CCH₃). ¹⁹**F NMR** (CDCl₃, 282 MHz, 298 K): δ (ppm) = -99.6 (WF). ³¹**P NMR** (CDCl₃, 121 MHz, 298 K): δ (ppm) = 11.2 (s, br, WC*P*), 8.2 (s, br, WC*P*). **IR** (ATR, cm⁻¹): 2524 (w, BH), 1884 (s, CO). **IR** (THF, cm⁻¹): 2546 (w, BH), 1896 (s, CO). **Anal.** Calc. for C₄₅H₄₈BFN₆OP₂W (964.50 g/mol): C, 56.04; H, 5.02; N, 8.71. Found: C, 54.32; H, 5.85; N, 8.38.

1.4.4 5^{Cl}



In a 100 mL Schlenk flask, 760 mg (954 μ mol) **4**^{CI} dissolved in 60 mL THF were cooled to -80 °C and 0.50 mL (1.25 mmol) of a 2.5 M n-BuLi solution in hexane were added. After ten minutes, 0.28 mL (1.52 mmol) Ph₂PCI was added. After coming to room temperature and removing the solvent *in vacuo*, the crude product was purified by column

chromatography with CH_2Cl_2 /petroleum ether 1/1 as eluent. After drying *in vacuo*, the target compound **5**^{ci} was obtained as a green powder. Yield: 817 mg (87 %).

¹**H NMR** (CDCl₃, 300 MHz, 298 K): δ (ppm) = 8.10 (m, 2 H, Ph-*H*), 7.43 (m, 3 H, Ph-*H*), 7.28-7.02 (m, 9 H, Ph-*H*), 6.79 (m, 2 H, Ph-*H*), 6.65 (m, 2 H, Ph-*H*), 6.50 (m, 2 H, Ph-*H*), 2.57 (s, 3 H, CH₃), 2.57 (s, 3 H, CH₃), 2.42 (d, 3 H, CH₃, J_{HP} = 1.70 Hz), 2.20 (s, 3 H, CH₃), 2.15 (s, 3 H, CH₃), 2.12 (s, 3 H, CH₃), 1.95 (s, 3 H, CH₃), 1.78 (s, 3 H, CH₃), 1.54 (s, 3 H, CH₃), 2.15 (s, 3 H, CH₃), 2.12 (s, 3 H, CH₃), 1.95 (s, 3 H, CH₃), 1.78 (s, 3 H, CH₃), 1.54 (s, 3 H, CH₃). ¹³**C NMR** (CDCl₃, 75 MHz, 298 K): δ (ppm) = 235.4 (CO), 217.0 (dd, WCP, ¹J_{CP} = 50.0 Hz, ³J_{CP} = 6.4 Hz), 211.3 (dd, WCP, ¹J_{CP} = 45.4 Hz, ³J_{CP} = 4.5 Hz), 151.7, 151.6, 150.3, 143.6, 141.3, 140.0 (^{3.5}CCH₃), 138.8-133.2, 129.3-126.9 (Ph-C), 113.6, 113.1, 113.0 (⁴CH), 15.9 (d, J_{CP} = 18.2 Hz), 15.1 (d, J_{CP} = 10.0 Hz), 14.3, 11.3, 11.0, 10.5, 8.6, 8.2, 8.1 (CCH₃). ³¹**P NMR** (CDCl₃, 121 MHz, 299 K): δ (ppm) = 17.3 (d, WCP, ³J_{PP} = 10.4 Hz), 16.7 (d, WCP, ³J_{PP} = 10.4 Hz). **IR** (ATR, cm⁻¹): 2547 (w, BH), 1909 (s, CO). **IR** (THF, cm⁻¹): 2551 (w, BH), 1922 (s, CO). **Anal.** Calc. for C₄₅H₄₈BClN₆OP₂W (980.95 g/mol): C, 55.10; H, 4.93; N, 8.57. Found: C, 54.67; H, 4.95; N, 8.37.



In a 100 mL Schlenk flask, 500 mg (457 μ mol) **5**^{OTF} were dissolved in 50 mL MeCN. The reaction solution was heated for 30 min under reflux, while a colour change from turquoise to a deep green was os, brerved. After checking the progress of the conversion by IR, the solvent was removed *in vacuo*. The green residue was dissolved in 5 mL CH₂Cl₂, layered with 30 mL *n*-

pentane and then crystallised overnight. The supernatant was discarded and the crystals were dried *in vacuo*. Yield: 460 mg (89 %).

¹**H NMR** (CDCl₃, 300 MHz, 298 K): δ (ppm) = 7.74 (m, 2 H, Ph-*H*), 7.48 (m, 3 H, Ph-*H*), 7.34 (m, 3 H, Ph-*H*), 7.23-7.00 (m, 6 H, Ph-*H*), 6.80 (m, 2 H, Ph-*H*), 6.56 (m, 2 H, Ph-*H*), 6.46 (m, 2 H, Ph-*H*), 3.03 (s, 3 H, NCC*H*₃), 2.54 (s, 3 H, C*H*₃), 2.23 (s, 3 H,), 2.19 (s, 3 H, C*H*₃), 2.15 (d, 3 H, C*H*₃, J_{HP} = 2.08 Hz), 2.13 (s, 3 H, C*H*₃), 1.96 (s, 3 H, C*H*₃), 1.94 (s, 3 H, C*H*₃), 1.81 (s, 3 H, C*H*₃), 1.62 (s, 3 H, C*H*₃). ¹³**C NMR** (CDCl₃, 75 MHz, 298 K): δ (ppm) = 224.7 (m, CO), 214.9 (d, WCP, ¹J_{CP} = 6.4 Hz), 214.3 (d, WCP, ¹J_{CP} = 5.6 Hz), 152.4, 150.9, 150.5 (^{3.5}CCH₃), 150.3 (d, NCCH₃), 145.3, 144.1, 141.7 (^{3.5}CCH₃), 136.0-127.4 (Ph-C), 114.4, 114.4, 113.9 (⁴CH), 95.3 (q, CF₃, ¹J_{CF} = 485 Hz), 14.8, 14.7 (d, J_{CP} = 8.8 Hz), 14.0, 11.2, 11.0, 10.4, 8.4, 8.1, 7.9 (CCH₃), 4.8 (NCCCH₃). ¹⁹**F NMR** (CDCl₃, 282 MHz, 298 K): δ (ppm) = -78.2 (CF₃). ³¹**P NMR** (CDCl₃, 121 MHz, 298 K): δ (ppm) = 20.9, 20.1 (WC*P*). **IR** (ATR, cm⁻¹): 2562 (w, BH), 2276 (w, MeCN), 1927 (s, CO). **IR** (CH₂Cl₂, cm⁻¹): 2562 (w, BH), 1953 (s, CO). **Anal.** Calc. for C₄₈H₅₁BF₃N₇O₄P₂SW (1135.62 g/mol): C, 50.77; H, 4.53; N, 8.63; S, 2.82. Found: C, 50.89; H, 4.56; N, 8.23; S, 2.93.

1.5 Dinuclear Complexes [(5^L)PdCl₂]

1.5.1 [(5^{SPh})PdCl₂]



In a 100 mL Schlenk flask, a solution of 97 mg (340 μ mol) [(cod)PdCl₂] in 20 mL CH₂Cl₂ was added to a stirred solution of 358 mg (340 μ mol) **5**^{SPh} in 50 mL CH₂Cl₂. After one hour, the solvent was removed under reduced pressure and the residue was purified by column chromatography using an

eluent mixture of THF/petroleum ether 1/1. The brown product band was collected and dried *in vacuo*. Yield 208 mg (50 %).

¹**H NMR** (CDCl₃, 300 MHz, 299 K): δ (ppm) = 8.35 (m, br, 2 H, Ph-*H*), 7.62-6.98 (m, br, 23 H, Ph-*H*), 2.60 (s, 3 H, CH₃), 2.27 (s, 3 H, CH₃), 2.14 (s, 3 H, CH₃), 1.87 (s, br, 3 H, CH₃), 1.80 (s, br, 3 H, CH₃), 1.67 (s, br, 3 H, CH₃), 1.59 (s, 3 H, CH₃), 1.30 (s, 3 H, CH₃), 1.23 (s, 3 H, CH₃). ¹³**C NMR** (CDCl₃, 75 MHz, 299 K): δ (ppm) = 152.9, 152.9, 147.2, 142.3, 142.0, 142.0 (3,5 CCH₃), 137.1-125.3 (Ph-C), 116.8, 113.6, 112.4 (4 CH), 16.2, 14.9, 14.9, 11.2, 11.1, 11.0, 8.3, 8.2, 7.9 (CCH₃). ³¹**P NMR** (CDCl₃, 121 MHz, 299 K): δ (ppm) = 52.1 (d, WCP, $^{2}J_{PP}$ = 31.2 Hz), 43.2 (d, WCP, $^{2}J_{PP}$ = 31.2 Hz). **IR** (ATR, cm⁻¹): 2558 (w, BH), 1926 (s, CO). **IR** (CH₂Cl₂, cm⁻¹): 2562 (w, BH), 1949 (s, CO). **Anal.** Calc. for C₅₁H₅₃BCl₂N₆OP₂PdSW (1232.00 g/mol)·0.5 CH₂Cl₂: C, 48.53; H, 4.27; N, 6.59; S, 2.52. Found: C, 48.86; H, 4.54; N, 6.28; S, 2.24.

1.5.2 [(5^{CN})PdCl₂]



In a 50 mL Schlenk flask, a solution of 29 mg (102 μ mol) [(cod)PdCl₂] in 5 mL CH₂Cl₂ was slowly added to a stirred solution of 100 mg (103 μ mol) **5^{CN}** in 5 mL CH₂Cl₂. A colour change from green to yellow-brown was observed immediately. After one hour, the solvent was removed *in vacuo*, the residue was dissolved in

 $2 \text{ mL } \text{CH}_2\text{Cl}_2$ and layered with $40 \text{ mL } \text{Et}_2\text{O}$. The supernatant was separated from the precipitating ochre-coloured powder and the solid is dried *in vacuo*. Yield 112 mg (94 %).

¹**H NMR** (CDCl₃, 250 MHz, 300 K): δ (ppm) = 8.27-8.07 (m, 4 H, Ph-*H*), 7.70 (m, 3 H, Ph-*H*), 7.56-7.41 (m, 6 H, Ph-*H*), 7.29-7.19 (m, 5 H, Ph-*H*), 6.96 (m, 2 H, Ph-*H*), 2.66 (s, 3 H, C*H*₃), 2.53 (s, 3 H, C*H*₃), 2.39 (s, 3 H, C*H*₃), 2.16 (s, 3 H, C*H*₃), 1.76 (s, 3 H, C*H*₃), 1.75 (s, 3 H, C*H*₃), 1.42 (s, 3 H, C*H*₃), 1.38 (s, 3 H, C*H*₃), 0.92 (s, 3 H, C*H*₃). ¹³**C NMR** (CDCl₃, 63 MHz, 298 K): δ (ppm) = 243.2 (m, CO), 233.4 (m, WCP), 222.9 (m, WCP), 153.5, 152.4 ($^{3.5}$ CCH₃), 150.6 (CN), 146.6, 143.9, 143.9, 141.9 ($^{3.5}$ CCH₃), 136.6-121.9 (Ph-C), 114.0, 113.9, 113.0 (4 CH), 16.3, 15.3, 15.2, 11.3, 10.8, 10.8, 8.2, 8.1, 8.1 (CCH₃). ³¹**P NMR** (CDCl₃, 101 MHz, 298 K): δ (ppm) = 54.7 (d, WCP, $^{2}J_{PP}$ = 36.3 Hz), 46.1 (d, WCP, $^{2}J_{PP}$ = 32.7 Hz). **IR** (ATR, cm⁻¹): 2558 (w, BH), 2118 (w, CN), 1962 (s, CO). **IR** (CH₂Cl₂, cm⁻¹): 2562 (w, BH), 2114 (w, CN), 1976 (s, CO). **Anal.** Calc. for C₄₆H₄₈BCl₂N₇OP₂PdW (1148.84 g/mol)·CH₂Cl₂·CH₃CN: C, 46.16; H, 4.19; N, 8.79, Found: C, 46.48; H, 4.11; N, 8.26.



Figure S1. Correlation of the stretching frequency of the CO valence vibration with the mean ¹³C NMR shifts of the two W-bound alkyne carbon atoms.



Figure S2. Correlation of the stretching frequency of the CO valence vibration with the ¹³C NMR shifts of the W-bound CO ligand.

3 X-Ray Analysis

3.1 General information

In all figures, ellipsoids have been set at 50 % probability. Co-crystallized solvents, partial Poxidation and hydrogen atoms have been omitted while Ph-carbon atoms are depicted as ball-and-stick-models for clarity. Where multiple layers exist in the same structure, the one with the highest probability is depicted. Single crystals suitable for X-ray diffraction analysis were selected in Fomblin YR-1800 perfluoropolyether oil (Alfa Aesar) at ambient temperature and mounted on a glass fiber. During the measurement, the samples were cooled to 123(2) K. Diffraction data were collected on a Bruker D8 QUEST diffractometer and a Bruker Kappa Apex II diffractometer using graphite monochromated Mo-K α radiation (λ = 0.71073 Å). Structure solutions were found by direct methods (SHELXS-97 or SHELXS-2013)^{S3} and were refined by full-matrix least-squares procedures on F² (SHELXL-2013)^{S4} All non-hydrogen atoms were anisotropically refined unless stated otherwise. Hydrogen atoms were included at calculated positions with fixed thermal parameters unless stated otherwise.

3.2 Crystallographic Details, Figures and Selected Structural Parameters

3.2.1 [Tp*W(CO)L(η^2 -C₂H₂)] 3^L



Figure S3. Molecular structure of 3^{OTF} in the crystal. Selected bond lengths (Å): W1–N1 2.1453(14), W1–N3 2.2270(15), W1–N5 2.2266(14), W1–O1 2.1309(12), W1–C3 1.9707(19), W1–C1 2.0440(18), W1–C2 2.0221(18), C1–C2 1.293(3).

compound	3 ^{OTf}
empirical formula	C ₂₂ H ₃₀ BF ₃ N ₆ O ₄ SW
fw (g mol ⁻¹)	768.70
crystal size (mm)	0.50 × 0.16 × 0.03
crystal system	monoclinic
space group	P21/c
a (Å)	12.8417(5)
b (Å)	22.0759(8)
c (A)	11.0925(4)
α (deg)	
β (deg)	115.227(1)
γ(deg)	00440040
V (A ⁻)	2844.02(18)
\angle	4
μ (IIIII)	4.29
independent reflections	9000 4 10316
reflections with (>2 σ ())	10310
	0095
$R1$ ($F[l>2\sigma(l)]$)	0.042
wR2 (F ² [all data])	0.043
GOF	1.017
parameters	379
restraints	0
CCDC no.	2202261

3.2.2 [Tp*W(CO)L(η^2 -C₂{H}{PPh₃}] 4^L



Figure S4. Molecular structure of **4**^{SPh} in the crystal. Selected bond lengths (Å) and -angles (°): W1–N1 2.251(5), W1–N3 2.224(4), W1–N5 2.238(4), W1–S1 2.3884(14), W1–C21 1.946(4), W1–C1 2.043(5), W1– C2 2.069(5), C1–C2 1.311(7), P1–C2 1.787(5), C1– C2–P1 132.6(4).

Figure S5. Molecular structure of **4**^F in the crystal. Selected bond lengths (Å) and -angles (°): N1–W1 2.233(2), N3–W1 2.214(2), N5–W1 2.184(2), F1–W1 1.9636(19), C15–W1 2.001(4), C1–W1 2.030(3), C2– W1 2.059(3), C1–C2 1.310(5), C2–P1 1.793(3), C1– C2–P1 141.1(3).





Figure S6. Molecular structure of **4**^{CI} in the crystal. Selected bond lengths (Å) and -angles (°): W1–N1 2.220(3), W1–N3 2.235(3), W1–N5 2.207(3), W1–C11 2.4249(9), W1–C3 1.964(4), W1–C1 2.030(4), W1–C2 2.052(4), C1–C2 1.327(6), P1–C2 1.782(4), C1–C2–P1 133.9(3).

Figure S7. Molecular structure of **4**^{Br} in the crystal. Selected bond lengths (Å) and -angles (°): W1–N1 2.217(5), W1–N3 2.229(4), W1–N5 2.196(5), W1–Br1 2.5788(6), W1–C3 1.951(6), W1–C1 2.050(6), W1–C2 2.032(6), C1–C2 1.326(9), P1–C1 1.787(6), C2–C1–P1 133.3(5).

compound	4 ^{SPh}	4 ^F
empirical formula	C ₃₉ H ₄₄ BN ₆ OPSW	C ₃₃ H ₃₉ BFN ₆ OPW
fw (g mol ⁻¹)	870.49	780.33
crystal size (mm)	0.08 × 0.06 × 0.05	0.12 × 0.11 × 0.03
crystal system	Orthorhombic	Triclinic
space group	<i>P</i> 2 ₁ 2 ₁ 2 ₁	Pī
a (Å)	11.0623(9)	9.0234(8)
b (Å)	17.4935(17)	10.1907(9)
c (Å)	19.5062(19)	19.5548(18)
α (deg)		88.570(4)
β(deg)		77.444(5)
γ (deg)		69.035(4)
V (Å ³)	3818.0(6)	1636.2(3)
Z	4	2
$\mu ({\rm mm}^{-1})$	3.16	3.621
measured reflections	7553	53800
independent reflections	7553	11718
reflections with $l>2\sigma(l)$	6533	10164
R _{int}	0.077	0.0454
<i>R</i> 1 (F[<i>I</i> >2σ(<i>I</i>)])	0.037	0.0355
wR2 (F ² [all data])	0.073	0.0836
GOF	1.083	1.044
parameters	465	415
restraints	0	0
CCDC no.	2202262	2202263

compound	4 ^{CI}	4 ^{Br}	
empirical formula	C ₃₃ H ₃₉ BCIN ₆ OPW ·4CH ₂ Cl ₂	$C_{33}H_{39}BBrN_6OPW$ $\cdot C_5H_{12}$	
fw (g mol ⁻¹)	1136.48	913.38	
crystal size (mm)	0.45 × 0.14 × 0.09	0.21 × 0.12 × 0.11	
crystal system	orthorhombic	Orthorhombic	
space group	Pca2 ₁	Pca2₁	
a (Å)	16.460(3)	16.5493(5)	
b (Å)	10.3892(18)	10.3618(2)	
c (A)	22.022(4)	22.0549(6)	
α (deg)			
β (deg)			
γ (deg)			
$V(A^{\circ})$	3765.9(11)	3781.99(17)	
\angle -1	4	4	
$\mu (\text{mm}^{-1})$	3.79	4.19	
measured reflections	75214	41114	
independent reflections	15292	11985	
reflections with $l>2\sigma(l)$	13754	9887	
Rint	0.033	0.057	
$R1 (F[I>2\sigma(I)])$	0.025	0.035	
wR2 (F ² [all data])	0.066	0.068	
GOF	1.066	1.001	
parameters	407	397	
restraints	1	0	
CCDC no.	2203102	2202390	

3.2.3 [Tp*W(CO)L(η²-C₂{PPh₃}₂)] 5^L



Figure S8. Lower-quality refinement of the molecular structure of 5^{SMe} . Selected bond lengths (Å) and - angles (°): W1–N1 2.231, W1–N3 2.237, W1–N5 2.280, W1–S1 2.383, W1–C27 1,885, W1–C1 2.042, W1–C2 2.100, C1–C2 1.231, P1–C1 1.889, P2–C2 1.817, C2–C1–P1 142.71, C1–C2–P2 144.27.

Figure S9. Molecular structure of **5**^{SCPy} in the crystal. Selected bond lengths (Å) and -angles (°): W1–N1 2.272(2), W1–N3 2.228(2), W1–N5 2.202(2), W1–S1 2.3790(7), W1–C3 1.962(3), W1–C1 2.060(3), W1–C2 2.085(3), C1–C2 1.325(4), P1–C1 1.798(3), P2–C2 1.793(3), C2–C1–P1 135.2(2), C1–C2–P2 136.6(2).



Figure S10. Lower-quality refinement of the molecular structure of **5**^{SPh}. Selected bond lengths (Å) and - angles (°): W1–N1 2.197, W1–N3 2.248, W1–N5 2.247, W1–S1 2.397, W1–C27 2,015, W1–C1 2.077, W1–C2 2.082, C1–C2 1.382, P1–C1 1.769, P2–C2 1.786, C2–C1–P1 133.84, C1–C2–P2 134.65.

Figure S11. Molecular structure of **5**^F in the crystal. Selected bond lengths (Å) and -angles (°): W1–N1 2.2376(18), W1–N3 2.2231(18), W1–N5 2.1954(19), W1–F1 1.9618(15), W1–C3 1.958(2), W1–C1 2.048(2), W1–C2 2.076(2), C1–C2 1.327(3), P1–C1 1.786(2), P2–C2 1.795(2), C2–C1–P1 139.25(17), C1–C2–P2 139.35(17).



Figure S12. Molecular structure of **5**^{CI} in the crystal. Selected bond lengths (Å) and -angles (°): N1–W1 2.2291(15), N3–W1 2.2278(16), N5–W1 2.1778(16), W1–Cl1 2.4265(5), W1–C3 1.9641(19), W1–C1 2.0402(18), W1–C2 2.0595(18), C1–C2 1.331(2), P1– C1 1.7943(18), P2–C2 1.8001(18), C2–C1–P1 134.50(15), C1–C2–P2 136.01(15).

Figure S13. Molecular structure of 5^{Br} in the crystal. Selected bond lengths (Å) and -angles (°): W1–N1 2.2345(11), W1–N3 2.2340(11), W1–N5 2.1788(11), W1–Br1 2.58686(15), W1–C27 1.9667(13), W1–C1 2.0617(13), W1–C2 2.0405(13), C1–C2 1.3340(18), P1–C1 1.8010(13), P2–C2 1.7955(13), C2–C1–P1 135.17(10), C1–C2–P2 134.47(10).



Figure S14. Molecular structure of **5**^{OTT} in the crystal. Shown is one individual molecule of the asymmetric unit. Selected bond lengths (Å) and -angles (°): W1–N1 2.254(5), W1–N3 2.160(5), W1–N5 2.223(6), W1–O2 2.146(4), W1–C27 1.963(8), W1–C1 2.076(6), W1–C2 2.039(7), C1–C2 1.342(9), P1–C1 1.791(7), P2–C2 1.785(7), C2–C1–P1 133.8(6), C1–C2–P2 134.6(5).

Figure S15. Molecular structure of **5**^{MeCN}-**OTf** in the crystal. Selected bond lengths (Å) and -angles (°): W1–N2 2.164(3), W1–N4 2.233(3), W1–N6 2.201(3), W1–N1 2.126(3), W1–C3 1.976(3), W1–C1 2.057(3), W1–C2 2.034(3), C1–C2 1.330(5), P1–C1 1.793(3), P2–C2 1.790(3), C2–C1–P1 139.6(3), C1–C2–P2 136.3(3).



Figure S16. Molecular structure of **5^{Py}-OTf** in the crystal. Selected bond lengths (Å) and -angles (°): W1–N2 2.217(2), W1–N4 2.1733(19), W1–N6 2.224(2), W1–N1 2.193(2), W1–C3 1.977(3), W1–C1 2.026(2), W1–C2 2.061(2), C1–C2 1.337(3), P1–C1 1.795(2), P2–C2 1.797(2), C2–C1–P1 135.02(19), C1–C2–P2 134.23(19).

compound	5 ^{SCPy}	5 ^F	5 ^{CI}
empirical formula	$C_{51}H_{54}BN_7OP_2SW$	$C_{45}H_{48}BFN_6OP_2W$	C ₄₅ H ₄₈ BCIN ₆ OP ₂ W
	·2CH ₂ Cl ₂	·2CHCl₃	·0.893C ₅ H ₁₂ ·0.107CH ₂ Cl ₂
fw (g mol ⁻ ')	1239.52	1203.23	1054.46
crystal size (mm)	0.13 × 0.12 × 0.11	0.26 × 0.06 × 0.04	0.60 × 0.21 × 0.13
crystal system	triclinic	Triclinic	monoclinic
space group	Pī	Pī	P21/n
a (Å)	13.4082(13)	11.5877(10)	13.1334(6)
b (Å)	13.6770(13)	13.9252(12)	19.3491(8)
c (Å)	16.9058(16)	16.8414(15)	19.7000(8)
α (deg)	100.820(3)	86.448(4)	
β(deg)	94.524(4)	78.987(4)	99.355(2)
γ (deg)	113.869(3)	68.149(4)	
V (Å ³)	2743.0(5)	2475.7(4)	4939.6(4)
Z	2	2	4
$\mu ({\rm mm}^{-1})$	2.44	2.77	2.51
measured reflections	132596	80268	129485
independent reflections	19014	17837	17834
reflections with $l>2\sigma(l)$	15414	15081	15411
R _{int}	0.076	0.050	0.032
<i>R</i> 1 (F[<i>I</i> >2σ(<i>I</i>)])	0.040	0.032	0.025
wR2 (F ² [all data])	0.089	0.076	0.063
GOF	1.052	1.027	1.093
Parameters	587	515	558
Restraints	0	0	5
CCDC no.	2203103	2202267	2202268

compound	5 ^{Br}	5 ^{OTf}
empirical formula	C ₄₅ H ₄₈ BBrN ₆ OP ₂ W	C ₄₆ H ₄₈ BF ₃ N ₆ O ₄ P ₂ SW
$f_{\rm res} = (r_{\rm res} - 1)^{-1}$	·C5H12	·0.333 C ₅ H ₁₂ ·1.333 THF
crystal size (mm)	0.20 × 0.22 × 0.18	0.19 × 0.09 × 0.08
crystal system	monoclinic	Triclinic
space group	P2 ₁ /C	P1
a (A)	13.1304(4)	15.1651(9)
b (Å)	19.4822(6)	21.3862(12)
c (Å)	19.7195(6)	25.7029(16)
α (deg)		98.383(3)
β (deg)	99.166(1)	104.409(4)
γ (deg)		93.786(3)
$V(Å^3)$	4980.0(3)	7941.9(8)
Z	4	6
$\mu ({\rm mm}^{-1})$	3.23	2.346
measured reflections	219003	212014
independent reflections	18111	69859
reflections with $l>2\sigma(l)$	16485	56838
R _{int}	0.032	0.0679
R^{1} (F[/>2 σ (/)])	0.020	0.0419
wR2 (F ² [all data])	0.044	0.0888
GOF	1.066	0.985
parameters	523	3610
restraints	0	1449
CCDC no.	2221973	2203161

compound	5 ^{MeCN} -OTf	5 ^{Py} -OTf	
empirical formula	$C_{48}H_{51}BF_3N_7O_4P_2SW$	$C_{51}H_{53}BF_3N_7O_4P_2SW$	
		·2CH ₂ Cl ₂	
fw (g mol ⁻¹)	1135.61	1344.39	
crystal size (mm)	0.16 × 0.10 × 0.07	0.99 × 0.05 × 0.04	
crystal system	monoclinic	Triclinic	
space group	P21/n	Pī	
a (Å)	12.9737(6)	10.7634(5)	
b (Å)	20.0730(8)	15.6372(8)	
c (Å)	18.6793(9)	17.1562(9)	
α (deg)	90.0	81.843(2)	
β (deg)	92.342(2)	86.429(2)	
γ (deg)	90.0	81.767(2)	
$V(Å^3)$	4860.4(4)	2826.3(2)	
Z	4	2	
$\mu ({\rm mm}^{-1})$	2.548	2.379	
measured reflections	146718	136805	
independent reflections	14187	16463	
reflections with $l>2\sigma(l)$	11090	13958	
R _{int}	0.084	0.0723	
<i>R</i> 1 (F[<i>I</i> >2σ(<i>I</i>)])	0.0355	0.0303	
wR2 (F ² [all data])	0.0620	0.056	
GOF	1.057	1.043	
parameters	668	741	
restraints	294	59	
CCDC no.	2203105	2202269	

3.2.4 Dinuclear Complexes with Pd



Figure S17. Lower-quality refinement of the molecular structure of the molecular structure of (**5**^{SPh})**PdCl**₂ in the crystal. Selected bond lengths (Å) and -angles (°): W1–N1 2.207, W1–N3 2.237, W1–N5 2.238, W1–S1 2.358, W1–C27 1.997, W1–C1 2.063, W1–C2 2.078, P1–C1 1.804, P2–C2 1.804, Pd1–P1 2.247, Pd1–P2 2.246, Pd1–Cl1 2.349, Pd1–Cl2 2.369, C2–C1 P1 117.9, C1–C2–P2 119.0, P2–Pd1–P1 86.98, P1–Pd1–Cl1 88.26, Cl1–Pd1–Cl2 93.79, P2–Pd1–Cl2 90.77.

Figure S18. Molecular structure of (**5**^{Br})**PdCl**₂ in the crystal. Selected bond lengths (Å) and -angles (°): N1– W1 2.225(2), N3–W1 2.218(2), N5–W1 2.175(2), Br1– W1 2.5551(4), W1–C3 1.988(3), W1–C1 2.035(3), W1– C2 2.043(2), P1–C1 1.805(3), P2–C2 1.805(3), P1– Pd1 2.2477(7), P2–Pd1 2.2406(7), C11–Pd1 2.3363(8), Cl2–Pd1 2.3355(7), C2–C1–P1 118.16(19), C1–C2–P2 119.1(2), P2–Pd1–P1 87.77(3), P2–Pd1–Cl2 89.38(3), Cl2–Pd1–Cl1 93.35(3), P1–Pd1–Cl1 89.32(3).



Figure S19. Molecular structure of $(5^{CN})PdCl_2$ in the crystal. Selected bond lengths (Å) and -angles (°): W1–N1 2.215(3), W1–N3 2.218(2), W1–N5 2.180(3), W1–C4 2.143(3), W1–C3 2.000(3), W1–C1 2.020(3), W1–C2 2.057(3), P1–C1 1.807(3), P2–C2 1.819(3), Pd1–P1 2.2335(8), Pd1–P2 2.2556(9), Pd1–Cl1 2.3407(11), Pd1–Cl2 2.3454(9), C2–C1–P1 120.2(2), C1–C2–P2 119.1(3), P1–Pd1–P2 88.82(3), P1–Pd1–Cl1 86.08(4), Cl1–Pd1–Cl2 93.33(4), P2–Pd1–Cl2 91.71(4).

Figure S20. Molecular structure of $(5^{Br})Pdl_2$ in the crystal. Selected bond lengths (Å) and -angles (°): N1–W1 2.231(3), N3–W1 2.222(3), N5–W1 2.164(2), Br1–W1 2.5396(4), W1–C3 1.981(3), W1–C1 2.051(3), W1–C2 2.036(3), P1–C1 1.825(3), P2–C2 1.803(3), P1–Pd1 2.2853(9), P2–Pd1 2.2730(9), Pd1–I1 2.6670(4), Pd1–I2 2.6320(4), C2–C1–P1 119.5(2), C1–C2–P2 119.9(2), P2–Pd1–P1 87.74(3), P1–Pd1–I1 92.95(2), I2–Pd1–I1 93.137(12), P2–Pd1–I2 86.01(2).

compound	(5 ^{Br})PdCl ₂	(5 ^{CN})PdCl₂	(5 ^{Br})Pdl ₂
ompirical formula	C ₄₅ H ₄₈ BBrCl ₂ N ₆ OP ₂ PdW	C46H48BCl2N7OP2PdW	$C_{45}H_{48}BBrl_2N_6OP_2PdW$
empilical lornula	\cdot 3 CH ₂ Cl ₂	$\cdot C_2H_3N\cdot CH_2CI_2$	$\cdot 2 \text{ CH}_2 \text{CI}_2$
fw (g mol ⁻¹)	1457.48	1222.36	1555.45
crystal size (mm)	0.21 × 0.10 × 0.03	0.10 × 0.10 × 0.03	0.36 × 0.13 × 0.07
crystal system	monoclinic	Triclinic	monoclinic
space group	P2 ₁ /n	Pī	P21/c
a (Å)	15.3742(16)	13.5408(11)	12.7620(7)
b (Å)	16.4883(18)	13.7166(11)	15.7369(10)
c (Å)	21.753(2)	16.4682(12)	27.1915(16)
α (deg)		92.352(4)	90.0
β (deg)	91.629(3)	92.815(4)	100.596(2)
γ (deg)		119.240(4)	90.0
$V(Å^3)$	5512.0(10)	2658.3(4)	5367.9(6)
Z	4	2	4
$\mu ({\rm mm}^{-1})$	3.63	2.81	4.671
measured reflections	141896	85217	119210
independent reflections	19918	19133	17711
reflections with $l>2\sigma(l)$	15751	15229	13826
R _{int}	0.068	0.047	0.0498
<i>R</i> 1 (F[<i>l</i> >2σ(<i>l</i>)])	0.032	0.038	0.0331
w <i>R</i> 2 (F ² [all data])	0.076	0.095	0.0736
GOF	1.052	0.929	1.032
parameters	631	582	604
restraints	0	0	0
CCDC no.	2202264	2202265	2203104

4 NMR spectra of selected compounds

4.1 [Tp*W(CO)L(η^2 -C₂H₂)] 3^L

4.1.1 3^{SMePy}



Figure S21. ¹H NMR of 3^{SMePy} (CDCl₃, 500 MHz, 298 K). Note very broad CH₂ protons at ca. 5 ppm.



Figure S22. $^{\rm 13}{\rm C}$ NMR of $3^{\rm SMePy}$ (CDCl_3, 63 MHz, 299 K).





Figure S23. ¹H NMR of **3^{Br}** (CDCl₃, 300 MHz, 298 K).



Figure S24. $^{\rm 13}{\rm C}$ NMR of $3^{\rm Br}$ (CDCl_3, 75 MHz, 298 K).





Figure S25. 1 H NMR of 3^{OTf} (CDCl₃, 300 MHz, 298 K).



24



 $[Tp*W(CO)L(\eta^2-C_2{H}{PPh_3})] 4^{L}$

Figure S27. ¹⁹F NMR of 3^{0Tf} (CDCl₃, 282 MHz, 298 K).

4.2.1 4^{SMePy}

4.2



Figure S28. ¹H NMR of 4^{SMePy} (CDCl₃, 300 MHz, 298 K).



Figure S29. ¹³C NMR of 4^{SMePy} (CDCl₃, 63 MHz, 300 K). ¹³CO not resolved.



Figure S30. ³¹P NMR of **4**^{SMePy} (CDCl₃, 121 MHz, 298 K).





Figure S31. ¹H NMR of **4^{Br}** (CDCl₃, 300 MHz, 298 K).



Figure S32. ¹³C NMR of 4^{Br} (CDCI₃, 75 MHz, 298 K).



Figure S33. ³¹P NMR of 4^{Br} (CDCl₃, 121 MHz, 299 K).

4.2.3 4^{OTf}



Figure S34. ¹H NMR of **4**^{OTf} (C₆D₆, 300 MHz, 298 K). Low concentration due to low solubility.



Figure S35. ¹³C NMR of 4^{OTf} (C₆D₆, 63 MHz, 298 K). Low concentration due to low solubility.



Figure S36. ¹⁹F NMR of 4^{OTf} (C₆D₆, 282 MHz, 298 K). Low concentration due to low solubility.



Figure S38. ¹H NMR of 5^{SMePy} (CDCl₃, 300 MHz, 298 K). Note very broad CH₂ protons at ca. 5 ppm.

Figure S37. ³¹P NMR of 4^{OTf} (C₆D₆, 121 MHz, 298 K). Low concentration due to low solubility.

 $[Tp*W(CO)L(\eta^2-C_2{PPh_3}_2)]5^{L}$

4.3

4.3.1 5^{SMePy}





Figure S39. 13 C NMR of 5^{SMePy} (CDCl₃, 63 MHz, 300 K). 13 CH₂ not resolved.



Figure S40. ³¹P NMR of 5^{SMePy} (CDCl₃, 121 MHz, 298 K).





Figure S41. ¹H NMR of 5^{Br} (CDCl₃, 300 MHz, 298 K).



Figure S42. $^{\rm 13}{\rm C}$ NMR of ${\bf 5}^{\rm Br}$ (CDCl₃, 75 MHz, 298 K).



<17.5 17.4

 $<_{18.7}^{18.7}$





Figure S44. ^1H NMR of $\textbf{5}^{\text{OTf}}$ (CDCl_3, 500 MHz, 298 K).



Figure S45. ¹³C NMR of 5^{0Tf} (CDCl₃, 126 MHz, 298 K).



Figure S46. ¹⁹F NMR of 5^{0Tf} (CDCl₃, 471 MHz, 298 K).



Figure S47. ³¹P NMR of 5^{0Tf} (CDCl₃, 202 MHz, 298 K).

4.4 (5^{Br})PdCl₂



Figure S48.¹H NMR of $(5^{Br})PdCl_2$ (CD₂Cl₂, 300 MHz, 298 K).



Figure S49. ¹³C NMR of (5^{Br})PdCl₂ (CD₂Cl₂, 75 MHz, 299 K).



Figure S50. ³¹P NMR of (5^{Br})PdCl₂ (CD₂Cl₂, 121 MHz, 299 K).

4 References

- S1 Kai Helmdach, Stephan Ludwig, Alexander Villinger, Dirk Hollmann, Jutta Kösters and Wolfram W. Seidel, *Chem. Commun.*, **2017**, 53, 5894–5897.
- S2 N. G. Connelly and W. E. Geiger, *Chem. Rev.*, **1996**, 96, 877–910.
- S3 G. M. Sheldrick, *SHELXS-2013, Program for Solution of Crystal Structure*, Univ. Göttingen, **2013**.
- S4 G. M. Sheldrick, *SHELXL-2013, Program for Refinement of Crystal Structure*, Univ. Göttingen, **2013**.